Phosphorus
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Phosphorus was a New York City computational-genomics company founded in 2016 by Alexander Bisignano and Santiago Munne, the co-founders of Recombine (sold to CooperSurgical for $85 million). It built a genomic data network and medical-grade genetic tests: HeartMap, LipidMap and, for consumers, GeneCompass ($249, analysing 400+ genes for cancer risk, disease predisposition and drug response). During COVID it pivoted to at-home saliva testing (FDA EUA June 2020), then shut the COVID business in January 2022 to focus on preventive genomics. It raised about $18 million (a $10 million Series A led by FirstMark Capital).
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Alexander Bisignano and Santiago Munne found Phosphorus in New York after selling Recombine to CooperSurgical; it closes a $10 million Series A led by FirstMark Capital.
- COVID testing pivot
Phosphorus obtains FDA emergency authorisation for an at-home saliva COVID test and launches GeneCompass for consumers.
- COVID exit; Kindbody acquisition
Phosphorus shuts its COVID-19 testing business (last samples January 14, 2022) to focus on preventive genomics; fertility company Kindbody acquires Phosphorus Labs, bringing its lab and team in-house as KindLabs.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.